These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

752 related items for PubMed ID: 9661602

  • 1. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.
    Azziz R, Black V, Hines GA, Fox LM, Boots LR.
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2317-23. PubMed ID: 9661602
    [Abstract] [Full Text] [Related]

  • 2. Androgen response to hypothalamic-pituitary-adrenal stimulation with naloxone in women with myotonic muscular dystrophy.
    Buyalos RP, Jackson RV, Grice GI, Hockings GI, Torpy DJ, Fox LM, Boots LR, Azziz R.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3219-24. PubMed ID: 9745431
    [Abstract] [Full Text] [Related]

  • 3. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [Abstract] [Full Text] [Related]

  • 4. Adrenocortical secretion of dehydroepiandrosterone in healthy women: highly variable response to adrenocorticotropin.
    Azziz R, Fox LM, Zacur HA, Parker CR, Boots LR.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2513-7. PubMed ID: 11397848
    [Abstract] [Full Text] [Related]

  • 5. Effects of aging on adrenal function in the human: responsiveness and sensitivity of adrenal androgens and cortisol to adrenocorticotropin in premenopausal and postmenopausal women.
    Parker CR, Slayden SM, Azziz R, Crabbe SL, Hines GA, Boots LR, Bae S.
    J Clin Endocrinol Metab; 2000 Jan; 85(1):48-54. PubMed ID: 10634362
    [Abstract] [Full Text] [Related]

  • 6. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R, Black VY, Knochenhauer ES, Hines GA, Boots LR.
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [Abstract] [Full Text] [Related]

  • 7. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome.
    Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, Chrousos GP, Gold PW.
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1224-34. PubMed ID: 1659582
    [Abstract] [Full Text] [Related]

  • 8. Alterations in the hypothalamic-pituitary-ovarian and the hypothalamic-pituitary-adrenal axes in athletic women.
    Loucks AB, Mortola JF, Girton L, Yen SS.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):402-11. PubMed ID: 2537332
    [Abstract] [Full Text] [Related]

  • 9. Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome.
    Yildiz BO, Woods KS, Stanczyk F, Bartolucci A, Azziz R.
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5558-62. PubMed ID: 15531511
    [Abstract] [Full Text] [Related]

  • 10. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism.
    Azziz R, Rafi A, Smith BR, Bradley EL, Zacur HA.
    J Clin Endocrinol Metab; 1990 Feb; 70(2):431-6. PubMed ID: 2137133
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome.
    Lanzone A, Fulghesu AM, Guido M, Cucinelli F, Caruso A, Mancuso S.
    Fertil Steril; 1997 Jan; 67(1):34-9. PubMed ID: 8986680
    [Abstract] [Full Text] [Related]

  • 12. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone.
    Lanzone A, Guido M, Ciampelli M, Fulghesu AM, Pavone V, Proto C, Caruso A, Mancuso S.
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141
    [Abstract] [Full Text] [Related]

  • 13. Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans.
    Dorin RI, Ferries LM, Roberts B, Qualls CR, Veldhuis JD, Lisansky EJ.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3883-91. PubMed ID: 8923833
    [Abstract] [Full Text] [Related]

  • 14. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.
    Puurunen J, Piltonen T, Jaakkola P, Ruokonen A, Morin-Papunen L, Tapanainen JS.
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1973-8. PubMed ID: 19318449
    [Abstract] [Full Text] [Related]

  • 15. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess.
    Moran C, Reyna R, Boots LS, Azziz R.
    Fertil Steril; 2004 Jan; 81(1):126-31. PubMed ID: 14711555
    [Abstract] [Full Text] [Related]

  • 16. Comparison of adrenocorticotropin and adrenal steroid responses to corticotropin-releasing hormone versus metyrapone testing in patients with hypopituitarism.
    Riddick L, Chrousos GP, Jeffries S, Pang S.
    Pediatr Res; 1994 Aug; 36(2):215-20. PubMed ID: 7970937
    [Abstract] [Full Text] [Related]

  • 17. Relative sensitivity and responsivity of serum cortisol and two adrenal androgens to alpha-adrenocorticotropin-(1-24) in normal and obese, nonhirsute, eumenorrheic women.
    Komindr S, Kurtz BR, Stevens MD, Karas JG, Bittle JB, Givens JR.
    J Clin Endocrinol Metab; 1986 Oct; 63(4):860-4. PubMed ID: 3018027
    [Abstract] [Full Text] [Related]

  • 18. Sex-related differences in stimulated hypothalamic-pituitary-adrenal axis during induced gonadal suppression.
    Roca CA, Schmidt PJ, Deuster PA, Danaceau MA, Altemus M, Putnam K, Chrousos GP, Nieman LK, Rubinow DR.
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4224-31. PubMed ID: 15886244
    [Abstract] [Full Text] [Related]

  • 19. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome.
    Ditkoff EC, Fruzzetti F, Chang L, Stancyzk FZ, Lobo RA.
    J Clin Endocrinol Metab; 1995 Feb; 80(2):603-7. PubMed ID: 7852527
    [Abstract] [Full Text] [Related]

  • 20. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
    Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A, Guido M.
    Fertil Steril; 2007 Jul; 88(1):131-8. PubMed ID: 17336978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.